Valuation: Alumis Inc.

Market Cap 3.57B 3.14B 2.92B 2.68B 5.03B 344B 5.1B 34.62B 13.53B 169B 13.4B 13.11B 584B P/E 2026 *
-9.74x
P/E 2027 * -10.2x
Enterprise Value 3.04B 2.67B 2.48B 2.28B 4.27B 292B 4.34B 29.44B 11.5B 144B 11.39B 11.15B 497B EV / Sales 2026 *
388x
EV / Sales 2027 * 134x
Free-Float
96.22%
Yield 2026 *
-
Yield 2027 * -
1 day-1.06%
1 week-2.30%
Current month-0.50%
1 month+12.68%
3 months+12.31%
6 months+14.19%
Current year+186.89%
1 week 26.94
Extreme 26.94
30.11
1 month 24.71
Extreme 24.71
31.35
Current year 7.85
Extreme 7.85
31.35
1 year 3.75
Extreme 3.75
31.35
3 years 2.76
Extreme 2.7601
31.35
5 years 2.76
Extreme 2.7601
31.35
10 years 2.76
Extreme 2.7601
31.35
Manager TitleAgeSince
Chief Executive Officer 61 2021-09-22
Director of Finance/CFO 60 2022-04-30
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 63 2021-04-30
Director/Board Member 60 2021-05-31
Chairman 61 2021-09-22
Date Insider Type Main position Quantity % Market Cap.
7/6/26 Fiscal year

General Counsel

15,000 0.0122%
6/30/26 Free

Director

19,081 0.0155%
6/30/26 Free

Director

19,081 0.0155%
Change 5-day change 1-year change 3-year change Capi.($)
-1.06%-2.30%+625.39% - 3.57B
+0.93%+6.97%+62.83%+67.97% 57.28B
-1.92%+6.03%+43.68%+84.56% 54.99B
-0.46%-1.29%+3.28%+422.58% 23.18B
-2.97%-2.35%-22.03%-16.54% 22.59B
-0.36%+5.73%+30.99%-3.58% 20.46B
-1.34%+0.51%+25.02%-30.27% 17.56B
-1.44%+5.67%+32.54%+544.11% 15.67B
-1.30%-5.02%+165.62%+291.37% 14.46B
-0.50%-0.98%+23.62%+178.38% 13.92B
Average -1.04%+0.92%+99.10%+170.95% 24.37B
Weighted average by Cap. -0.87%+2.03%+49.74%+135.69%

Financials

2026 *2027 *
Net sales 7.82M 6.86M 6.38M 5.86M 11.01M 753M 11.18M 75.81M 29.62M 370M 29.34M 28.71M 1.28B 23.83M 20.93M 19.47M 17.86M 33.57M 2.3B 34.08M 231M 90.32M 1.13B 89.48M 87.55M 3.9B
Net income -375M -329M -306M -281M -528M -36.1B -536M -3.64B -1.42B -17.75B -1.41B -1.38B -61.36B -397M -348M -324M -297M -559M -38.21B -567M -3.85B -1.5B -18.79B -1.49B -1.46B -64.95B
Net Debt -534M -469M -437M -401M -753M -51.47B -764M -5.18B -2.03B -25.3B -2.01B -1.96B -87.49B -371M -326M -303M -278M -522M -35.7B -530M -3.6B -1.4B -17.55B -1.39B -1.36B -60.69B
Logo Alumis Inc.
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Employees
226
Date Price Change Volume
26-07-24 US$28.00 -1.06% 1,164,915
26-07-23 US$28.30 -1.77% 649,986
26-07-22 US$28.81 -4.13% 813,442
26-07-21 US$30.05 +7.40% 875,471
26-07-20 US$27.98 -2.37% 694,593
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
28.00USD
Average target price
40.10USD
Spread / Average Target
+43.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALMS Stock